Empagliflozin attenuates coronary atherosclerosis by promoting the differentiation of pericoronary adipose-derived stem cells

28 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Emerging pharmacologic strategies in coronary artery disease: anti-inflammatory, antithrombotic, and cardiometabolic approaches Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology